Literature DB >> 2418652

Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT.

P Jenner, J A Pratt, C D Marsden.   

Abstract

Clonazepam is a potent anticonvulsant 1,4-benzodiazepine that controls some types of myoclonus. Its primary mode of action is to facilitate GABAergic transmission in the brain by a direct effect on benzodiazepine receptors. GABA receptors lie on the cell bodies of dorsal raphe neurons, and GABA acts to inhibit raphe cell firing, an action potentiated by benzodiazepines. Clonazepam does not alter 5-HT synthesis but decreases 5-HT utilization in brain and blocks the egress of 5-HIAA from the brain. It is not known whether the actions of clonazepam in altering 5-HT function are responsible for its antimyoclonic action, since these are observed only after large doses. Also, the effects of clonazepam are the exact opposite of those predicted from the beneficial effects of 5-HTP in human myoclonic disorders. Finally, why clonazepam, more than other benzodiazepines, is of benefit in the treatment of myoclonus is not clear. This may be due to some pharmacokinetic feature of the drug in conjunction with its potency at benzodiazepine receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418652

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  12 in total

1.  Norpethidine induced myoclonus in a patient with renal failure.

Authors:  D C Reutens; E G Stewart-Wynne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

Review 2.  Use of sleep-promoting medications in nursing home residents : risks versus benefits.

Authors:  David K Conn; Robert Madan
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Post anoxic action myoclonus.

Authors:  A J Larner; M T Heafield
Journal:  J R Soc Med       Date:  1993-05       Impact factor: 5.344

Review 4.  Pharmacological options for the treatment of Tourette's disorder.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Clonazepam for the management of sleep disorders.

Authors:  Alberto Raggi; Maria Paola Mogavero; Lourdes M DelRosso; Raffaele Ferri
Journal:  Neurol Sci       Date:  2022-09-16       Impact factor: 3.830

Review 6.  Physiology-Based Treatment of Myoclonus.

Authors:  Ashley B Pena; John N Caviness
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 7.  Treatment of myoclonus.

Authors:  John N Caviness
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 8.  Post-hypoxic Myoclonus: Current Concepts, Neurophysiology, and Treatment.

Authors:  Harsh V Gupta; John N Caviness
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-09-17

9.  Vertigo/dizziness as a Drugs' adverse reaction.

Authors:  Serafina Chimirri; Rossana Aiello; Carmela Mazzitello; Laura Mumoli; Caterina Palleria; Mariolina Altomonte; Rita Citraro; Giovambattista De Sarro
Journal:  J Pharmacol Pharmacother       Date:  2013-12

10.  Treatment of Generalized Anxiety Disorder with Gabapentin.

Authors:  Matej Markota; Robert J Morgan
Journal:  Case Rep Psychiatry       Date:  2017-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.